Abstract
RET fusions occur in 1-2% of non-small-cell lung cancers (NSCLCs), which are associated with unique clinical features and poor prognosis and may contribute to resistance to EGFR-TKIs. Despite the development of highly potent RET inhibitors, the genetic architecture of primary and secondary RET fusions in NSCLCs remains to be systematically elucidated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
